In preclinical studies, weekly dosing with a number of EGFR inhibitors, including erlotinib and gefitinib, EGFR inhibitors were equally effective as daily dosing in breast, bladder and colon cancer models, and potentially more effective in two lung cancer models (Lubet et al., 2013; Zhang et al., 2017; Mohammed et al., 2020; Ulusan et al., 2021). Here, EGFR is linked to lung carcinoma.